Karyopharm Therapeutics Inc. (KPTI) · Nov 2, 2026 · Bankruptcy
Chapter 11 filing — Prepackaged plan provides no distribution to common or preferred stockholders
Karyopharm’s bankruptcy filing names Ayrmid as lead bidder and secures $55 million in DIP financing, but the plan provides no recovery for current equity holders.
Karyopharm entered this filing as a cash-constrained commercial-stage oncology company, trying to fund XPOVIO while advancing its myelofibrosis program. Its June 2026 filing had already warned that liquidity would fund operations only into September, with major debt and interest payments due and substantial doubt about continued operations; lenders then granted a temporary forbearance while the company pursued financing or strategic alternatives.
The strategic-alternatives process has become a court-supervised restructuring. Karyopharm has filed voluntary Chapter 11 petitions and signed a Restructuring Support Agreement that makes Ayrmid the lead bidder for a merger with a reorganized company. The sale process remains open to competing bids, so Ayrmid is not yet the final owner, but the business is no longer pursuing a conventional financing or partnership solution. 〔0〕
The operating business gets a bridge, not a recovery for shareholders. Up to $55 million of debtor-in-possession financing is intended to keep operations and patient-support activities running during the case. That preserves the commercial platform and pipeline long enough for a sale, but DIP financing sits ahead of existing equity and does not change the stated capital-structure outcome.
For current equity holders, the filing is effectively an announced wipeout. The company explicitly says the prepackaged plan provides no payment or other distribution to common or convertible-preferred holders and expects existing equity securities to have no value. 〔1〕 This is materially worse than the earlier “find financing or strategic alternatives” framing: the business may survive under a new owner, but the existing ownership claim is not part of that survival. 〔2〕
Bottom line: The filing changes Karyopharm from a distressed biotech seeking a financing solution into a bankrupt company being sold through Chapter 11. The $55 million bridge may protect operations and medicines, but it does not preserve value for existing shareholders; the overall company story is overturned.
Court approval of DIP financing and bidding procedures
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!